The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
The Microsatellite Instable Subset of Colorectal Cancer Is a Particularly Good Candidate for Checkpoint Blockade Immunotherapy
Open accessAbstract
Summary: The microsatellite instable (MSI) subset of colorectal cancer exhibits an active Th1/CTL immune microenvironment, probably due to recognition of a high number of tumor neoantigens. However, the high expression of checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, and IDO in MSI colorectal cancer distinguishes MSI from microsatellite stable colorectal cancer and creates an immunosuppressive microenvironment that may help MSI tumors evade immune destruction by the infiltrating immune cells. Though colorectal cancer does not have a good response rate to PD-1 pathway immunotherapy, these results suggest that the MSI subset of colorectal cancer is a particularly good candidate for checkpoint immunotherapy. Cancer Discov; 5(1); 16–8. ©2015 AACR. See related article by Llosa et al., p. 43
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has also shown significant benefit from immune checkpoint blockade therapy, anti-PD1/PDL1 (refs. 9,10).”
From A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients (2021) · cites this paper as [9]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, increasing evidence suggested that MSI tumors were responsive to immunotherapy of anti-PD1/PDL19,10.”
From A tumor microenvironment-specific gene expression signature predicts chemotherapy resistance in colorectal cancer patients (2021) · cites this paper as [9]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kostic, A. D., Chun, E., Robertson, L., Glickman, J. N., Gallini, C. A., Michaud, M., Clancy, T. E., Chung, D. C., Lochhead, P., Hold, G. L., et al. (2013) · Cell Host & Microbe · doi:10.1016/j.chom.2013.07.007 · Cited by 2,718
Taube, J. M., Anders, R. A., Young, G. D., Xu, H., Sharma, R., McMiller, T. L., Chen, S., Klein, A. P., Pardoll, D. M., Topalian, S. L., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003689 · Cited by 2,157
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationLandon, M., Saam, J. R., Brown, K. L., Moyes, K., Evans, B. A., & WENSTRUP, R. J. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,943
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Ogino, S., Nosho, K., Kirkner, G. J., Kawasaki, T., Meyerhardt, J. A., Loda, M. F., Giovannucci, E. L., & Fuchs, C. S. (2008) · Gut · doi:10.1136/gut.2008.155473 · Cited by 772
Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer
Prendergast, G. C., Smith, C., Thomas, S., Mandik‐Nayak, L., Laury‐Kleintop, L. D., Metz, R. A., & Muller, A. J. (2014) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-014-1549-4 · Cited by 491
Fusobacterium in Colonic Flora and Molecular Features of Colorectal Carcinoma
Tahara, T., Yamamoto, E., Suzuki, H., Maruyama, R., Chung, W., Garriga, J., Jelinek, J., Yamano, H.-O., Sugai, T., An, B., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-1865 · Cited by 465
Microsatellite Instability and BRAF Mutation Testing in Colorectal Cancer Prognostication
Lochhead, P. J., Kuchiba, A., Imamura, Y., Liao, X., Yamauchi, M., Nishihara, R., Qian, Z. R., Morikawa, T., Shen, J., Meyerhardt, J. A., et al. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt173 · Cited by 442
Human papillomavirus as a prognostic factor in carcinoma of the penis
Bezerra, A. L. R., Lopes, A., Hidalgo, G. S., Ribeiro, K. B., Latorre, M. R. D. O., & Villa, L. L. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12 · Cited by 206
Flagged first, then by citations
Cited by
Sorted by citations
Items 301–374 of 374
Miller, G., & Stebbing, J. (2017) · Oncogene · doi:10.1038/onc.2017.388 · Cited by 2
Quantifying the Limits of Immunotherapies in Mice and MenPreprint
Brown, L., Gaffney, E. A., Ager, A., Wagg, J., & Coles, M. C. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/759167 · Cited by 2
Is tumor mutational burden predictive of response to immunotherapy?Preprint
Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2024) · eLife · doi:10.7554/elife.87465.2 · Cited by 2
Alshammary, A. F., Al-Toub, M., Albukhari, T. A., & Filimban, W. A. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815124606123010009 · Cited by 1
Evaluation of immune infiltrate according to the HER2 status in colorectal cancer
Molimard, C., Dor, F., Overs, A., Monnien, F., Gessain, G., Kedochim-Augier, L., D’Angelo, F., Abad, M., Heberle, M., Dérangère, V., et al. (2023) · Digestive and Liver Disease · doi:10.1016/j.dld.2023.09.015 · Cited by 1
Araújo-Filho, I. (2024) · Journal of Clinical Immunology & Microbiology · doi:10.46889/jcim.2024.5308 · Cited by 1
Hermansyah, I., & Zulfikar, E. (2021) · JIMKI Jurnal Ilmiah Mahasiswa Kedokteran Indonesia · doi:10.53366/jimki.v9i1.339 · Cited by 1
CRISPR: A Promising Tool for Cancer Therapy
Mohammad‐Rafiei, F., Safdarian, E., Adel, B., Vandchali, N. R., Navashenaq, J. G., & Hayat, S. M. G. (2022) · Current Molecular Medicine · doi:10.2174/1566524022666220624111311 · Cited by 1
Prognostic significance of PD-L1 expression in patients with colorectal cancer: a meta-analysis*
Liu, S., Ma, R., Cao, H., Chen, D., Jing, C., Wang, Z., Zhang, J., Wu, Y., Feng, J., & Wu, J. (2019) · Oncology and Translational Medicine · doi:10.1007/s10330-018-0312-2 · Cited by 1
Vaincre les résistances aux antagonistes de checkpoint en augmentant l’immunogénicité de la tumeur
Marabelle, A. (2021) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2021.02.002 · Cited by 1
Concentrations of TIM-3 protein and its ligand Galectin-9 in patients
Chetveryakov, A. V., & Львович, Ц. В. (2022) · Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia» · doi:10.25557/0031-2991.2022.02.52-58 · Cited by 1
The role of obesity in macrophage-mediated mechanisms promoting early-onset colon cancer.
Scheurlen, K. M. (2022) · ThinkIR: The University of Louisville's Institutional Repository (University of Louisville) · doi:10.18297/etd/3850 · Cited by 2
Is tumor mutational burden predictive of response to immunotherapy?Preprint
Gurjao, C., Tsukrov, D. I., Imakaev, M., Luquette, L. J., & Mirny, L. A. (2023) · eLife · doi:10.7554/elife.87465 · Cited by 2
Karlsen, V. T., Majid, U., Lindholm, H. T., Umu, S. U., Vander-Elst, K. R., Beitnes, A.-C. R., Merok, M. A., Hagen, K. T., Nilsen, H. R., Yaqub, S., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.03.31.646286 · Cited by 1
µ Seq: Universal mutation rate quantification via deep sequencing of a single clonal expansionPreprint
Pompei, S., Geroldi, A., Rivetti, P., Grassi, E., Vurchio, V., Tallarico, G., Corti, G., Tattini, L., Liti, G., Bertotti, A., et al. (2025) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2025.04.17.649315 · Cited by 1
Epigenetic alterations in sporadic and familial cancers
Joensuu, E. I. (2015) · Työväentutkimus Vuosikirja
New hope on the horizon for patients with metastatic colorectal cancer
Abdel-Rahman, O. M., Azim, H. A., Mikhail, S., & Salem, M. E. (2015) · Colorectal Cancer · doi:10.2217/crc.15.28
Assessment of Biomarkers’ Predictive Value of Efficacy
Rouleau, E., Callens, C., Pierron, G., & Bièche, I. (2015) · Springer eBooks · doi:10.1007/978-3-319-22189-2_7
The Outlook for Immune Checkpoint Targeting Strategies in Colorectal Cancer
Morse, M. A. (2016) · Current Colorectal Cancer Reports · doi:10.1007/s11888-016-0309-6
Rolle des Pathologen in Hinblick auf therapeutische Entscheidungen beim Magenkarzinom
Tharun, L., Steuer, S., & Quaas, A. (2016) · Der Onkologe · doi:10.1007/s00761-016-0033-5
Genetics of Ovarian Carcinomas
Sénéchal, C., Buecher, B., Pauw, A. D., Houdayer, C., Rouleau, É., Noguès, C., & Stoppa‐Lyonnet, D. (2016) · Springer eBooks · doi:10.1007/978-3-319-32110-3_2
Berghoff, A. S., Kather, J. N., & Jäger, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-62431-0_13
Luk, I. Y. (2017) · Minerva Access (University of Melbourne)
Future Therapies in Medical Oncology
Paik, J. C., Kin, C., & Fisher, G. A. (2017) · Springer eBooks · doi:10.1007/978-4-431-55579-7_7
Medical Oncology Management of Hereditary Colorectal Cancer
Vilar, E., Salazar, R., & Tabernero, J. M. (2018) · Springer eBooks · doi:10.1007/978-3-319-74259-5_25
Immune Checkpoint Inhibitors Against Colon Cancer
Muro, K. (2018) · Nihon Daicho Komonbyo Gakkai Zasshi · doi:10.3862/jcoloproctology.71.406
Therapy Response Imaging in Gastrointestinal Malignancy
Kawamoto, S. (2020) · Medical radiology · doi:10.1007/978-3-030-31171-1_7
Li, T., Hui, W., Halike, H., & Gao, F. (2020) · doi:10.21203/rs.3.rs-101882/v1
Regulation of Anti-Tumor Immunity and Immunotherapy Response In Colorectal Cancer
Zhao, X. (2020) · University of Minnesota Digital Conservancy (University of Minnesota)
Li, Z., Mao, K., Ding, B., & Xue, Q. (2021) · Preprints.org · doi:10.20944/preprints202108.0366.v1
Regulation of KCNQ1 and CFTR in Colorectal Cancer
Madden, R. (2019) · University of Minnesota Digital Conservancy (University of Minnesota)
Chen, C., & Wang, X. (2022) · Research Square · doi:10.21203/rs.3.rs-1264750/v1
Condelli, V., Calice, G., Cassano, A., Basso, M., Rodriquenz, M. G., Zupa, A., Maddalena, F., Crispo, F., Pietrafesa, M., Aieta, M., et al. (2020) · doi:10.21203/rs.3.rs-74746/v1
Alabedi, A. F., Hassan, A. J., & Yasear, A. Y. (2022) · International Journal of Health Sciences · doi:10.53730/ijhs.v6ns1.5840
Shrikhande, A., Sørensen, S. G., Offman, J., Domanska, B., Pedersen, J. S., & Hoffmann, E. R. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.04.28.489863
Chen, C., & Wang, X. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3986700
3) Immune Checkpoint Inhibitors for Gastrointestinal Tract Cancers
Muro, K. (2019) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.108.1777
Li, Z., Mao, K., Ding, B., & Xue, Q. (2021) · Preprints.org · doi:10.20944/preprints202108.0366.v2
Prognostic implication and immunological value of contactin 1 expression in pan‐cancer
Zhang, L., Zhang, J., Liu, T., Zhang, J., & Cui, Y. (2022) · Clinical and Translational Discovery · doi:10.1002/ctd2.70
Pan, Y.-B., Xu, W., Teng, Y., Gong, J., Fu, X.-Y., Feng, Y., Mao, X., & Li, S.-W. (2022) · Research Square · doi:10.21203/rs.3.rs-2234626/v1
Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy
Soto, L. M. S., & Wang, H. (2022) · Springer eBooks · doi:10.1007/978-3-030-80962-1_115-1
Luo, W., Gu, R., Fang, H., Zhang, R., Gan, L., Mo, S., & Li, Q. (2023) · Clinical and Translational Discovery · doi:10.1002/ctd2.166
2. Systemic Pharmacotherapy for Gastrointestinal Cancers
Muro, K. (2022) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.111.469
Moutafi, M. K., Koliou, G.-A., Papaxoinis, G., Economopoulou, P., Kotsantis, I., Gkotzamanidou, M. A., Anastasiou, Μ., Pectasides, D. G., Kyrodimos, E., Delides, A., et al. (2023) · doi:10.1158/2767-9764.c.6745835.v1
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802314
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802311
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802305
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802302
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802296
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802299
Mahgoub, E., Taneera, J., Ahmed, S. B., Hafezi, S., Venkatachalam, T., Hachim, M. Y., Sulaiman, N. D., Hamoudi, R., & Saber-Ayad, M. M. (2024) · F1000Research · doi:10.12688/f1000research.150115.1
Biological and molecular targets for targeted therapy in colorectal cancer (literature review)
Malovanna, A., Kolesnik, O., Zvirych, V. V., & Trehub, Y. S. (2024) · Practical oncology · doi:10.22141/2663-3272.7.1.2024.96
Immunotherapeutic strategies for the treatment of colorectal cancer
Parisi, A., Arrichiello, G., Salati, M., & Petrillo, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13376-3.00003-4
Therapeutic Advances in Gastrointestinal Cancers: Immuno-oncology and Beyond
Jalali, S. (2024) · EMJ Oncology · doi:10.33590/emjoncol/pxtf9170
Research Progress of M6A Methylation Modification in Immunotherapy of Colorectal Cancer
Zheng, J., Chen, Y., Peng, X., Wei, Z., Zhang, Y., Hei, F., & Lü, Z. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096332984250221071109
MicroRNAs and target genes as regulators of colon cancer immune signaling
Kit, O. I., Gvaldin, D. Y., Petrusenko, N. A., Тимошкина, Н. Н., Savchenko, D. A., & Novikova, I. A. (2025) · Medical Immunology (Russia) · doi:10.15789/1563-0625-mat-3150
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802329
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802341
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802335
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802338
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802332
Zhou, L., Zhang, Y., Wei, M., Du, K., Lin, J., & Wei, L. (2023) · Figshare · doi:10.6084/m9.figshare.23930242
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802317
Zhou, L., Zhang, Y., Wei, M., Du, K., Lin, J., & Wei, L. (2023) · Figshare · doi:10.6084/m9.figshare.23930239
Zhou, L., Zhang, Y., Wei, M., Du, K., Lin, J., & Wei, L. (2023) · Figshare · doi:10.6084/m9.figshare.23930236
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802323
Luo, W., Xiang, W., Gan, L., Che, J., Li, J., Wang, Y., Han, L., Gu, R., Ye, L., Wang, R., et al. (2022) · Figshare · doi:10.6084/m9.figshare.19802320
Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy
Soto, L. M. S., & Wang, H. (2025) · Springer eBooks · doi:10.1007/978-3-032-00761-2_115
Ishani, K., Wangmo, D., Ali, A. M., Gates, T. J., Yan, Z., Gustafson, A. P., Boytim, E., Storey, K. L., Goffredo, P., Hwang, J., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.02.03.703597
Ponamgi, S. P. D., & Peela, S. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-27765-8.00009-6
Balogoun, R. (2019) · theses.fr (ABES) · doi:10.70675/b078c676z06b0z4093za0f0zf4b5ac1484fb
Long-term regulation of colorectal cancer cells under mechanical stress
Mouelhi, M. (2023) · theses.fr (ABES) · doi:10.70675/c4c32dd5zfd5ez4187za887z25dd0c7e3452
Zahran, A. M., Elsherbiny, N. M., Abdelhakeem, A. G., Rayan, A., Mahran, Z. G., Elsayh, A. K. I., Saad, E., Refaat, A., Torky, R. A., Gamal, D. A., et al. (2026) · Clinical & Translational Oncology · doi:10.1007/s12094-026-04468-5
Metadata
- Authors
- Xiao, Y., & Freeman, G. J.
- Affiliations
- Harvard University (US)
- Corresponding author
- Freeman, Gordon J.
- ORCID
- Freeman, Gordon J.
- Venue
- Cancer Discovery
- Published
- 2015-01-01
- Volume
- 5
- Issue
- 1
- Pages
- 16-18
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC4295637
- OpenAlex
- W2042797183
- Cited by
- 368
- References
- 11
- Citations by year
- 2026: 5 · 2025: 13 · 2024: 17 · 2023: 26 · 2022: 54 · 2021: 44 · 2020: 36 · 2019: 46 · 2018: 35 · 2017: 40 · 2016: 37 · 2015: 14
- FWCI
- 18.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- U.S. Public Health Service (HHSN272201100018C)
- National Cancer Institute (U54CA163125, P50CA101942)
- National Institute of Allergy and Infectious Diseases (HHSN272201100018C, P01AI056299)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- microsatellite instability, colorectal cancer, immune checkpoint blockade, PD-1, PD-L1, CTLA-4, LAG-3, IDO, tumor immune microenvironment, neoantigens, immunosuppression, immunotherapy response
- MeSH terms
- Colonic Neoplasms, Humans, Microsatellite Instability, Tumor Microenvironment, Cell Cycle Checkpoints
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review